- Trials with a EudraCT protocol (204)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (9)
204 result(s) found for: Paroxysmal.
Displaying page 8 of 11.
EudraCT Number: 2007-001722-27 | Sponsor Protocol Number: D1250C00042 | Start Date*: 2007-10-11 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: Long-term treatment with the oral direct thrombin inhibitor AZD0837, compared to Vitamin-K antagonists, as stroke prevention in patients with non-valvular atrial fibrillation and one or more risk f... | |||||||||||||
Medical condition: Paroxysmal persistent or permanent non-valvular atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DK (Prematurely Ended) SE (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000484-86 | Sponsor Protocol Number: 02022018 | Start Date*: 2019-01-16 | |||||||||||||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||||||||||||
Full Title: DAN-WAR-D Danish Warfarin-Dialysis Study Safety and efficacy of warfarin in patients with atrial fibrillation on dialysis - A nationwide parallel-group open randomized clinical trial | |||||||||||||||||||||||
Medical condition: Atrial fibrillation, end-stage renal disease, and stroke | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001723-36 | Sponsor Protocol Number: D1250C0051 | Start Date*: 2007-10-16 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A controlled, randomized, parallel, multi-centre, feasibility study of the oral direct thrombin inhibitor AZD0837, given as extended-release formulation, in the prevention of stroke and systemic em... | |||||||||||||
Medical condition: This is a phase II study to evaluate the feasibility of conducting a study in patients with AF who are appropriate for, but unable or unwilling to take VKA therapy. The intended indication for th... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003771-35 | Sponsor Protocol Number: UX007G-CL201 | Start Date*: 2014-02-11 | |||||||||||
Sponsor Name:Ultragenyx Pharmaceutical Inc | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Study to Assess the Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome | |||||||||||||
Medical condition: Glucose Transporter Type 1 deficiency syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) GB (Completed) FR (Ongoing) HU (Completed) ES (Completed) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002338-35 | Sponsor Protocol Number: 144 | Start Date*: 2013-05-06 | |||||||||||
Sponsor Name:Biosense Webster, Inc. | |||||||||||||
Full Title: ATrial FibrillaTion ProgrESsion Trial (ATTEST Trial) | |||||||||||||
Medical condition: Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) ES (Completed) IE (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001484-79 | Sponsor Protocol Number: RIVAROXAFL3002 | Start Date*: 2013-02-06 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Open-label, Active-controlled Multi-center Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation | |||||||||||||
Medical condition: Prevention of stroke and non-CNS systemic embolism in patients with nonvalvular atrial fibrillation who undergo catheter ablation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002075-33 | Sponsor Protocol Number: ENRICH-AF | Start Date*: 2020-05-05 | ||||||||||||||||
Sponsor Name:Hamilton Health Sciences, through its Population Health Research Institute | ||||||||||||||||||
Full Title: Edoxaban for intracranial hemorrhage survivors with atrial fibrillation | ||||||||||||||||||
Medical condition: High risk atrial fibrillation patients with previous intracranial hemorrhage | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NO (Prematurely Ended) DE (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned) SK (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001256-20 | Sponsor Protocol Number: ITI 101724 | Start Date*: 2005-11-03 |
Sponsor Name:GlaxoSmithKline Research and Development Ltd. | ||
Full Title: A randomized, double blind, double dummy, parallel group, placebo controlled study to evaluate the pharmacodynamic and pharmacokinetic response and safety and tolerability of SB424323 (250 mg, 375 ... | ||
Medical condition: Non-valvular Atrial Fibrillation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) GB (Completed) EE (Completed) HU (Completed) DK (Completed) LV (Completed) IT (Completed) DE (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-001129-17 | Sponsor Protocol Number: LDLL300.301 | Start Date*: 2017-06-19 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:AOP Orphan Pharmaceuticals GmbH | ||||||||||||||||||||||||||||||||||||||
Full Title: A multicenter, open-label study to investigate the effectiveness and safety of AOP Landiolol in controlling supraventricular tachycardia in pediatric patients (LANDI-PED). | ||||||||||||||||||||||||||||||||||||||
Medical condition: Supraventricular tachycardia in pediatric patients. | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: AT (Completed) DE (Ongoing) LT (Completed) HU (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-001866-39 | Sponsor Protocol Number: NOE-TGN-201 | Start Date*: 2022-02-24 | |||||||||||
Sponsor Name:Noema Pharma | |||||||||||||
Full Title: A Phase II/III, multicentre, 8-week run-in phase followed by a 12- week, prospective, parallel-group, double-blind, randomized withdrawal, placebo-controlled study, with a 52 week open label exten... | |||||||||||||
Medical condition: Trigeminal neuralgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DK (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000174-19 | Sponsor Protocol Number: 9345 | Start Date*: 2015-01-27 |
Sponsor Name:Universitätsklinikum Ulm | ||
Full Title: Efficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia (EMAA) who are treated with Ciclosporin A Prospective Randomized Multicenter Study comparing Thrombopoetin-Re... | ||
Medical condition: Moderate Aplastic Anemia (MAA) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-004999-36 | Sponsor Protocol Number: BCBe/04/FRO-CLU/001 | Start Date*: 2006-11-06 | |||||||||||
Sponsor Name:Berlin-Chemie AG | |||||||||||||
Full Title: Effects of Frovatriptan as Prophylactic Treatment of Cluster Headache, a Multi-Center, Placebo Controlled, Randomized, Double-Blind Prospective Phase III Parallel-Group Trial Comparing Frovatriptan... | |||||||||||||
Medical condition: Episodic cluster headache | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010208-27 | Sponsor Protocol Number: CLCZ696B2214 | Start Date*: 2009-06-29 | |||||||||||
Sponsor Name:Novartis Farmacéutica S.A | |||||||||||||
Full Title: Estudio aleatorizado, doble ciego, multicéntrico, de grupos paralelos, controlado con tratamiento activo de doce semanas de seguimiento para evaluar la eficacia, seguridad y tolerabilidad de LCZ696... | |||||||||||||
Medical condition: Insuficiencia Cardiaca crónica | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) NL (Completed) IT (Completed) PL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019058-42 | Sponsor Protocol Number: LITIO-SUM-FC-002 | Start Date*: 2010-05-26 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI | |||||||||||||
Full Title: Safety of sumatriptan in combination with lithium for treatment of cluster headache, Pilot Study,Phase II | |||||||||||||
Medical condition: Cluster Headache | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000752-32 | Sponsor Protocol Number: 04T-617 | Start Date*: 2006-01-23 | |||||||||||
Sponsor Name:Klinikum Grosshadern | |||||||||||||
Full Title: Medical treatment of Menière’s disease with betahistine: a placebo-controlled, dose-finding study | |||||||||||||
Medical condition: Ménière’s disease is a disorder of the inner ear membranous labyrinth characterized by paroxysmal vertiginous attacks, fluctuating sensorineural hearing loss, aural fullness, and tinnitus .The unde... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002154-67 | Sponsor Protocol Number: A-MANECE-2013 | Start Date*: 2013-12-26 | |||||||||||
Sponsor Name:Dra. Cristina Avendaño Solá | |||||||||||||
Full Title: RANDOMIZED CLINICAL TRIAL, PLACEBO COMPARED TO EVALUATE THE EFFICACY AND SAFETY OF MINOCYCLINE IN ANGELMAN SYNDROME (A-MANECE STUDY) | |||||||||||||
Medical condition: Angelman Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000359-41 | Sponsor Protocol Number: D1250C00007 | Start Date*: 2004-08-31 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Controlled, Randomised, Parallel, Multicentre Study to Assess Safety and Tolerability of the Oral Direct Thrombin Inhibitor AZD0837 in the Prevention of Stroke and other Thromboembolic Complicati... | |||||||||||||
Medical condition: Prevention of stroke and other thromboembolic complications associated with Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001035-35 | Sponsor Protocol Number: CSPP100A2252 | Start Date*: 2009-06-04 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: a double blind, double dummy, randomized, multicenter, parallel group study to evaluate the Effects of aliSkiren, ramipril and combination treatment on plasma Concentration of Angiotensin II in Pat... | |||||||||||||
Medical condition: hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000248-91 | Sponsor Protocol Number: BTACH2012 | Start Date*: 2013-01-08 | |||||||||||
Sponsor Name:Institutt for nevromedisin, NTNU | |||||||||||||
Full Title: Endoscopic block of the sphenopalatine ganglion with botulinum toxin in intractable cluster headache. Safety issues. | |||||||||||||
Medical condition: Pharmacological refractory cluster headache with durations of periods of attacks normally more than 2 months | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006204-13 | Sponsor Protocol Number: PredCH | Start Date*: 2013-01-17 | |||||||||||
Sponsor Name:University of Duisburg-Essen | |||||||||||||
Full Title: Efficacy and safety of oral prednisone as add-on therapy in the prophylactic treatment of episodic cluster headache: a randomized, placebo controlled parallel study. | |||||||||||||
Medical condition: Episodic Cluster Headache (ECH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
